Business Context and Reporting Period
This Form 8-K filing by Cyclacel Pharmaceuticals, Inc. (CYCC) reports on the results of the 2025 Annual Meeting of Shareholders held on June 30, 2025. The registrant is incorporated in Delaware and maintains its principal executive offices in Kuala Lumpur, Malaysia. The filing addresses corporate governance matters, specifically the election of directors and shareholder approvals regarding equity plans and executive compensation.
Financial Metrics
This filing is a Current Report (Form 8-K) focused on corporate events and does not contain financial statements. Consequently, the document provides no data regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no material financial changes reported in this document. The primary material events are the successful re-election of the board of directors and the shareholder approval of amendments to the company's equity incentive plan.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future operations. The document strictly details the voting outcomes of the annual meeting:
- Election of Directors: Shareholders re-elected all five nominees (Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj) with approximately 99.97% of votes cast in favor for each.
- Equity Incentive Plan Amendment: Shareholders approved an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant by 4,281,987. The proposal received 99.94% support.
- Executive Compensation: Shareholders approved the advisory vote on executive compensation with 99.95% support.
Key Facts for Investor Verification
- Verify the impact of the 4,281,987 share increase to the 2018 Equity Incentive Plan on potential future dilution.
- Confirm the composition of the Board of Directors following the re-election of the five directors for three-year terms.
- Note that this filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial health metrics.
- Observe the high level of shareholder support (approx. 99.9%+) across all voting items, indicating strong alignment with current management and governance proposals.